QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Arvinas, Inc. (ARVN)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
2

Do Nothing: fundamentalScore 2 and qualitativeScore 2 both sit below the required floor of 3, and the rendered shadow flag is false so no SHADOW_FST9 compensation applies; the chart independently offers no qualifying entry (price 6.92 below SMA20/50/200 with MACD -0.24 under its signal, a countertrend pullback limit under the trend-alignment rule, and no honest breakout anchor overhead).

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to degrade disease-causing proteins. Its pipeline includes Bavdegalutamide and ARV-471, targeting prostate and breast cancer, respectively. The company collaborates with major pharmaceutical firms like Pfizer and Genentech.

Fundamental

weak
Fundamental2
Elevated risk profile

Arvinas has a speculative risk profile with no recurring revenue and a reliance on further equity issuance.

Clinical-stage PROTAC biotech with essentially no recurring revenue now that all legacy collaborations have terminated, burning roughly $59M a quarter, offset by $558.9M of cash and securities, no debt and a runway into the second half of 2028. Headline profitability is inflated by one-time collaboration revenue and the discounted-cash-flow models return negative values, making further equity issuance close to certain; a speculative, elevated-risk profile with a real but finite balance-sheet cushion.

Sentiment

weak
Sentiment2
Marginally negative sentiment

Media sentiment has cooled slightly, and there is no clear retail sentiment due to blocked data access.

Arvinas is a no-forward-driver setup anchored by a bearish, already-digesting Q3 2026 print (announced 2026-11-03: revenue down 98.8% year-over-year to $0.5M with a wider loss) plus a fresh capital_structure overhang from up to $200M in potential stock sales disclosed under a broader offering plan (2026-11-03, announced), with a determinate but mild negative sentiment delta (baseline polarity_score +0.15, n=6, to scoring polarity_score -0.05, n=16) and an indeterminate retail read (Reddit returned 403 on both attempts). Red-Flag Screen: no severe and no moderate flag fired, so no cap was applied - the soft read comes from the evidence itself rather than from a ceiling.

Technical

weak
Technical2
Weak-bearish chart

The stock is in a downtrend, trading below major moving averages with no confirmed reversal.

Weak-bearish chart with a two-session oversold bounce, not a qualifying bullish setup. Price 6.92 sits below SMA20 7.26, SMA50 7.77, SMA200 9.49, EMA9 7.02, EMA21 7.25 and both WMAs, with only DEMA14 6.88 / TEMA14 6.80 underneath — a bounce inside a decline that has run from ~13.60 in March to a 6.33 low on 2026-11-09. Momentum is repairing but has not turned: RSI14 43.68 (from 34.99), Williams %R -65.29 (from -98.18), MACD -0.24/-0.19 with histogram -0.05, i.e. line below zero and below its signal. ADX14 18.91 is sub-25, so read together with the MA stack it describes a choppy drift lower rather than a directional trend. Volume confirms the weakness: the -11.84% and -3.46% down days traded 1.26M and 1.21M shares while the +2.37% up day traded 0.70M. ATR14 0.45 = 6.50% of price, so range is adequate and not degenerate. Scored 2 (mostly weak-bearish, bounce-only). The chart is in any case not the binding constraint: fundamentalScore 2 and qualitativeScore 2 both fail the Step 00 override floors, and the rendered shadow flag is false, so no SHADOW_FST9 sum-compensation is available.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.